Literature DB >> 23190510

An overview of regular dialysis treatment in Japan (as of 31 December 2010).

Shigeru Nakai1, Kunitoshi Iseki, Noritomo Itami, Satoshi Ogata, Junichiro James Kazama, Naoki Kimata, Takashi Shigematsu, Toshio Shinoda, Tetsuo Shoji, Kazuyuki Suzuki, Masatomo Taniguchi, Kenji Tsuchida, Hidetomo Nakamoto, Hiroshi Nishi, Seiji Hashimoto, Takeshi Hasegawa, Norio Hanafusa, Takayuki Hamano, Naohiko Fujii, Ikuto Masakane, Seiji Marubayashi, Osamu Morita, Kunihiro Yamagata, Kenji Wakai, Atsushi Wada, Yuzo Watanabe, Yoshiharu Tsubakihara.   

Abstract

A nationwide statistical survey of 4226 dialysis facilities was conducted at the end of 2010, and 4166 facilities (98.6%) responded. The number of new patients introduced into dialysis was 37,512 in 2010. This number has decreased for two consecutive years since it peaked in 2008. The number of patients who died in 2010 was 28,882, which has been increasing every year. The number of patients undergoing dialysis at the end of 2010 was 298,252, which is an increase of 7591 (2.6%) compared with that at the end of 2009. The number of dialysis patients per million at the end of 2010 was 2329.1. The crude death rate of dialysis patients in 2010 was 9.8%, and has been gradually increasing. The mean age of the new patients introduced into dialysis was 67.8 years and the mean age of the entire dialysis patient population was 66.2 years. Regarding the primary disease of the new patients introduced into dialysis, the percentage of patients with diabetic nephropathy was 43.6%, which is a slight decrease from that in the previous year (44.5%). Patients with diabetic nephropathy as the primary disease accounted for 35.9% of the entire dialysis patient population, which approaches the percentage of patients with chronic glomerulonephritis as the primary disease (36.2%). The percentage of patients who had undergone carpal tunnel release surgery (CTx) was 4.3%, which is a slight decrease from that at the end of 1999 (5.5%). The decrease in the percentage of patients who had undergone CTx was significant among the patients with dialysis durations of 20-24 years (1999, 48.0%; 2010, 23.2%). A total weekly Kt/V attributable to peritoneal dialysis and their residual functional kidney was 1.7 or higher for 59.4% of patients who underwent peritoneal dialysis.
© 2012 The Authors. Therapeutic Apheresis and Dialysis © 2012 International Society for Apheresis.

Entities:  

Mesh:

Year:  2012        PMID: 23190510     DOI: 10.1111/j.1744-9987.2012.01143.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  40 in total

Review 1.  APOE polymorphism and diabetic nephropathy.

Authors:  Shin-ichi Araki
Journal:  Clin Exp Nephrol       Date:  2013-09-13       Impact factor: 2.801

Review 2.  Novel biomarkers for the progression of diabetic nephropathy: soluble TNF receptors.

Authors:  Tomohito Gohda; Yasuhiko Tomino
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

3.  Automated peritoneal dialysis for a patient with hearing loss: a case report.

Authors:  Tsutomu Sakurada; Shigeki Kojima; Daisuke Oishi; Kenichiro Koitabashi; Yugo Shibagaki; Kenjiro Kimura
Journal:  Perit Dial Int       Date:  2015 Mar-Apr       Impact factor: 1.756

4.  Re-embedding catheter technique at the discontinuation of peritoneal dialysis.

Authors:  Tsutomu Sakurada; Nagayuki Kaneshiro; Takanori Otowa; Daisuke Oishi; Kenichiro Koitabashi; Katsuomi Matsui; Yusuke Konno; Yuichi Sato; Yugo Shibagaki; Kenjiro Kimura
Journal:  Perit Dial Int       Date:  2015 May-Jun       Impact factor: 1.756

5.  Rehabilitation improves prognosis and activities of daily living in hemodialysis patients with low activities of daily living.

Authors:  Misako Endo; Yuya Nakamura; Takuya Murakami; Hideki Tsukahara; Yoshinobu Watanabe; Yoshiyuki Matsuoka; Isao Ohsawa; Hiromichi Gotoh; Takae Inagaki; Emiko Oguchi
Journal:  Phys Ther Res       Date:  2017-02-25

6.  Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.

Authors:  Tetsuya Ogawa; Himiko Shimizu; Ai Kyono; Masayo Sato; Tetsuri Yamashita; Kuniaki Otsuka; Kosaku Nitta
Journal:  Int Urol Nephrol       Date:  2013-06-27       Impact factor: 2.370

7.  Association between warfarin use and incidence of ischemic stroke in Japanese hemodialysis patients with chronic sustained atrial fibrillation: a prospective cohort study.

Authors:  Minako Wakasugi; Junichiro James Kazama; Akihide Tokumoto; Kensuke Suzuki; Shinji Kageyama; Kaoru Ohya; Yoshiaki Miura; Mamoru Kawachi; Takuma Takata; Masaaki Nagai; Minoru Ohya; Keiko Kutsuwada; Hideo Okajima; Isei Ei; Sachio Takahashi; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2013-10-11       Impact factor: 2.801

8.  Long-term effects of spironolactone in peritoneal dialysis patients.

Authors:  Yasuhiko Ito; Masashi Mizuno; Yasuhiro Suzuki; Hirofumi Tamai; Takeyuki Hiramatsu; Hiroshige Ohashi; Isao Ito; Hirotake Kasuga; Masanobu Horie; Shoichi Maruyama; Yukio Yuzawa; Tatsuaki Matsubara; Seiichi Matsuo
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

9.  Factors affecting the progression of renal dysfunction and the importance of salt restriction in patients with type 2 diabetic kidney disease.

Authors:  Noriko Kanauchi; Susumu Ookawara; Kiyonori Ito; Satsuki Mogi; Izumi Yoshida; Masafumi Kakei; San-E Ishikawa; Yoshiyuki Morishita; Kaoru Tabei
Journal:  Clin Exp Nephrol       Date:  2015-04-29       Impact factor: 2.801

10.  Replication study for the association of 3 SNP loci identified in a genome-wide association study for diabetic nephropathy in European type 1 diabetes with diabetic nephropathy in Japanese patients with type 2 diabetes.

Authors:  Shiro Maeda; Minako Imamura; Mahiro Kurashige; Shinichi Araki; Daisuke Suzuki; Tetsuya Babazono; Takashi Uzu; Tomoya Umezono; Masao Toyoda; Koichi Kawai; Masahito Imanishi; Kazushige Hanaoka; Hiroshi Maegawa; Yasuko Uchigata; Tatsuo Hosoya
Journal:  Clin Exp Nephrol       Date:  2013-03-30       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.